Previous Article | Next Article 
Molecular and Cellular Biology, October 1998, p. 6075-6082, Vol. 18, No. 10
0270-7306/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Biased Suppression of Hematopoiesis and Multiple Developmental
Defects in Chimeric Mice Containing Shp-2 Mutant Cells
Cheng-Kui
Qu,1,2,3
Wen-Mei
Yu,1,2,3
Biagio
Azzarelli,4
Scott
Cooper,2,3,5
Hal
E.
Broxmeyer,2,3,5 and
Gen-Sheng
Feng1,2,3,*
Departments of Biochemistry and Molecular
Biology,1
Pathology and Laboratory
Medicine,4 and
Microbiology and
Immunology5 and
Walther Oncology
Center,2 Indiana University School of
Medicine, Indianapolis, Indiana 46202-5254, and
Walther
Cancer Institute, Indianapolis, Indiana 462083
Received 12 May 1998/Returned for modification 16 June
1998/Accepted 16 July 1998
 |
ABSTRACT |
Shp-2 is a cytoplasmic tyrosine phosphatase that contains two Src
homology 2 (SH2) domains at the N terminus. Biochemical data suggests
that Shp-2 acts downstream of a variety of receptor and
cytoplasmic tyrosine kinases. A targeted deletion mutation in the
N-terminal SH2 (SH2-N) domain results in embryonic lethality of
homozygous mutant mice at midgestation. In vitro embryonic stem (ES)
cell differentiation assays suggest that Shp-2 might play an
important role in hematopoiesis. By aggregating homozygous mutant
(Shp-2
/
) ES cells and wild-type (WT) embryos,
we created Shp-2
/
-WT chimeric animals. We
report here an essential role of Shp-2 in the control of blood
cell development. Despite the widespread contribution of mutant cells
to various tissues, no Shp-2
/
progenitors for
erythroid or myeloid cells were detected in the fetal liver and bone
marrow of chimeric animals by using the in vitro CFU assay.
Furthermore, hematopoiesis was defective in
Shp-2
/
yolk sacs. In addition, the
Shp-2 mutation caused multiple developmental defects in
chimeric mice, characterized by short hind legs, aberrant limb
features, split lumbar vertebrae, abnormal rib patterning, and
pathological changes in the lungs, intestines, and skin. These results
demonstrate a functional involvement of Shp-2 in the
differentiation of multiple tissue-specific cells and in body
organization. More importantly, the requirement for Shp-2 is
more stringent in hematopoiesis than in other systems.
 |
INTRODUCTION |
Mammalian hematopoiesis occurs in
successive waves at various anatomical sites during embryogenesis,
including the yolk sac and fetal liver, spleen, and bone marrow. It
remains to be understood, however, how this developmental scheme
functions at the molecular level. An important issue is the
identification of genes involved in the developmental decisions leading
to the commitment and differentiation of hematopoietic stem and
progenitor cells.
Much attention has been paid in recent years to genes that are
predominantly expressed in the hematopoietic compartment
(22). Inactivation of genes such as those for GATA-1,
GATA-2, Pu.1, c-Myb, SCL/tal-1, Ikaros, and AML-1 by gene targeting in
mouse embryonic stem (ES) cells has permitted the assessment of their roles in hematopoiesis in mutant mouse models (8, 16, 21, 23, 30,
37). However, the homozygous mutant mice often die early, at
midgestation, due to a failure of embryonic hematopoiesis, which
precludes detailed analysis of gene functions in blood cell development. Two experimental approaches, i.e., in vitro ES cell differentiation assay and chimeric animal analysis, have been used as
alternatives to gain insights into the roles of these genes in
hematopoiesis (11, 24, 27). GATA-1 deficiency leads to
developmental arrest and cell apoptosis at the proerythroblast stage,
and ablation of the GATA-2 gene suppresses the generation of all
definitive hematopoietic cell lineages in chimeric animals (37-39). SCL/tal-1 is a helix-loop-helix transcription
factor that was identified as a T-cell leukemia oncogene
(1). SCL/tal-1
/
ES cells failed to give rise
to erythrocytes, myeloid cells, megakaryocytes, and mast cells as well
as T and B lymphocytes either in vitro or in vivo in chimeric animals
(24, 27). These results suggest that SCL/tal-1 functions
very early in the hematopoietic hierarchy, possibly in the
specification of ventral mesoderm to blood cell progenitors (24,
27). Flk1 is a receptor tyrosine kinase that binds vascular
endothelial growth factor (VEGF) (4, 13), and
Flk1
/
embryos die at midsomite stage (32).
Chimeric analysis failed to detect the contribution of
Flk1
/
ES cells to any hematopoietic progenitor cells in
the yolk sac and fetal liver, strongly suggesting an intrinsic
requirement for Flk1 during primitive and definitive hematopoiesis
(31).
Programming of hematopoietic progenitor cell commitment and
differentiation is orchestrated to a large extent by environmental signals, particularly cytokines. Activated cytokine receptors transmit
signals from the cell surface into cells to elicit proper cellular
responses. However, little is known regarding the intracellular signal
transduction mechanisms involved in the control of hematopoiesis. Shp-2 is a widely expressed cytoplasmic tyrosine phosphatase
that contains two Src homology 2 (SH2) domains (6, 18).
Accumulating biochemical data suggests that Shp-2 participates
in signal transmission from a variety of cytokine receptors and might
function upstream of extracellular signal-regulated kinase (Erk)
(14, 19, 28, 33-36). To define the biological function of
Shp-2, we introduced a targeted mutation into the murine
Shp-2 locus, which resulted in an internal deletion
of 65 amino acids in the N-terminal SH2 (SH2-N) domain of Shp-2
(29). Homozygous Shp-2 mutant mice die at
midgestation with multiple defects in mesodermal patterning, while
heterozygous mutants appear normal. A similar phenotype was observed
through the microinjection of a catalytically inactive mutant mRNA of
Shp-2 into Xenopus embryos
(34). Taken together, these results suggest that the mutant
protein without the intact SH2-N domain does not function in a
dominant-negative manner but rather acts as a loss-of-function
molecule. To gain further insights into the role of Shp-2 in
the differentiation of hematopoietic and other cell lineages, we
isolated homozygous mutant (Shp-2
/
) ES cell
lines. By performing in vitro ES cell differentiation assays, we
demonstrated that the deletion mutation in the Shp-2 locus decreased the ability of primitive and definitive hematopoietic cells to develop in vitro (26).
However, it is not clear if the effect of the Shp-2 mutation on
blood cell development is cell autonomous. Since Shp-2 is ubiquitously expressed, it is also of great importance to define the
Shp-2 function in the later development of many other systems. In this study, we generated and characterized
Shp-2
/
-wild-type (WT) chimeric mice. Although
Shp-2
/
cells contributed to a wide variety of
tissues, accompanied by pathological changes, hematopoietic progenitor
cells of Shp-2
/
origin were barely detectable
in the bone marrow and fetal liver by using the CFU assay in vitro.
Furthermore, the hematopoietic activity was also defective in
Shp-2
/
yolk sacs. These results indicate
a more strict requirement for Shp-2 phosphatase in
mammalian hematopoiesis than in the differentiation of many other cell
types.
 |
MATERIALS AND METHODS |
Cell lines and animals.
A targeted mutant allele of
Shp-2 was created by homologous recombination in
mouse ES cell line R1 that deleted exon 3, coding for amino acid
residues 46 to 110 in the SH2-N domain of Shp-2 (29). Shp-2
/
ES cell lines were
generated by selection of Shp-2+/
cells in high
concentrations of G418 (15, 26). All ES cell lines were
maintained in complete ES cell medium containing 15% fetal calf serum
(FCS) (Hyclone, Logan, Utah) and 1,000 U of leukemia inhibitory factor
(LIF)/ml. CD-1 mice were purchased from Harlan Sprague Dawley
(Indianapolis, Ind.).
Generation of chimeric animals.
Shp-2+/+
and Shp-2
/
ES cells of 129/Sv origin were
aggregated with WT CD1 embryos to generate chimeric animals as
described previously (17). Mouse embryos at the eight-cell
stage, 2.5 days postcoitum (d.p.c.), were flushed from the oviduct.
After removal of the zonae pellucidae with Tyrode's solution,
individual embryos were aggregated with a gently trypsinized ES cell
clump (around eight cells) under a dissection microscope. These
aggregates were cultured in M16 medium overnight at 37°C, and the
aggregated embryos were then transferred into the uterus of a
2.5-d.p.c. pseudopregnant CD1 foster mother. Chimeric pups were
identified by the agouti color of their eyes and subsequently of the
coat hairs. Genotyping was performed by Southern blotting or PCR
analysis of genomic DNA extracted from embryos or various tissues of
chimeric animals (26, 29).
Hematopoietic progenitor assays.
To assess the contribution
of Shp-2
/
and Shp-2+/
ES
cells to hematopoietic progenitor cells in adult chimeras, bone marrow
cells were flushed out from two femurs of chimeric animals and
disaggregated into single-cell suspensions. Nucleated cells (5.0 × 104/ml) were seeded into a semisolid CFU assay culture
system as described elsewhere (2), which contains
-minimal essential medium (MEM), 30% FCS, 5% pokeweed
mitogen-stimulated mouse spleen cell conditioned medium, erythropoietin
(2 U/ml; Amgen Corp., Thousand Oaks, Calif.), murine stem cell factor
(SCF) (50 ng/ml; Immunex, Seattle, Wash.), glutamine (10
4
M),
-mecaptoethanol (3.3 × 10
5 M), hemin (100 µM; Eastman Kodak, Rochester, N.Y.), and 0.9% methylcellulose. CFU
assay cultures were incubated at 37°C in a 5% CO2
moisture-saturated incubator. After 6 to 7 days of incubation, colonies
from erythroid (BFU-E), granulocyte-macrophage (CFU-GM), and
multipotential (CFU-GEMM) progenitor cells were scored.
To detect hematopoietic progenitor cells in the fetal liver, individual
livers of chimeric embryos at 14.5 d.p.c. were dissected free of
other tissues in
-MEM plus 15% FCS, disaggregated mechanically into
single-cell suspensions, and washed in
-MEM containing 15% FCS.
Nucleated cells were subjected to CFU assay as described above.
For the assay of hematopoietic progenitors from yolk sacs, 8.5- to
9.0-d.p.c. yolk sacs were carefully dissected free of maternal tissues
under sterile conditions in
-MEM plus 15% FCS and were disaggregated by passing them through a 22-gauge needle with a syringe.
After being washed once in a
-MEM, whole yolk sac cells were plated
for CFU assay as above. Colonies from whole yolk sac cells were scored
after 7 days of incubation.
Skeletal preparation.
Newborn pups were eviscerated, fixed
in 100% ethanol for 4 days, kept in acetone for 3 days, and then
rinsed with water. The specimens were subsequently stained in alizarin
red S (0.005%), alcian blue 8GX (0.015%), acetic acid (5%), and
ethanol (85%) containing staining solution for 10 days. After brief
rinsing with water, the specimens were kept in 20% glycerol-1%
potassium hydroxide at 37°C for 24 h and then at room
temperature until tissues were completely cleared. Anatomical changes
were examined and photographed under a dissection microscope. Ossified
bones were stained red, while the cartilages were blue (12).
Histological analysis.
Whole embryos or surgically removed
tissue samples from chimeric mice at different stages were fixed in
10% buffered formalin, dehydrated through graded alcohol solutions,
embedded in paraffin, sectioned at 5 µm, and processed for
hematoxylin and eosin staining following standard protocols.
 |
RESULTS |
Generation of chimeric animals with Shp-2 mutant ES
cells.
Heterozygous (Shp-2+/
) and homozygous
(Shp-2
/
) mutant ES cell lines for the targeted
mutation were established as reported previously (26, 29).
Chimeric animals were generated by aggregating
Shp-2+/
or Shp-2
/
ES
cells with WT CD1 embryos (17). The production efficiencies of chimeric mice from Shp-2
/
and
Shp-2+/
ES cells at different developmental
stages were compared. Genotyping of embryos at 10.5 d.p.c.
indicated that 33 of 57 (58%) were
Shp-2
/
-WT chimeras, while 11 of 32 (34%)
were Shp-2+/
-WT chimeras. Therefore, the
chimera-forming efficiency of Shp-2
/
ES cells
was much higher than that of Shp-2+/
ES cells.
However, the numbers of newborn pups were similar for Shp-2+/
-WT (6 of 20 [30%]) and
Shp-2
/
-WT (19 of 68 [28%]) chimeras
(identified by the agouti coloring of their eyes). The differences
between the frequency in embryos and that in the viable births suggest
a partial embryonic lethality of Shp-2
/
-WT
chimeras. Indeed, we found that some heavily chimeric animals died in
utero between 10.5 and 12.5 d.p.c. (Fig.
1), with a phenotype similar to that of
the Shp-2
/
embryos, with severe defects in
mesodermal patterning and development of axial structures
(29). On the other hand, the higher frequency of
Shp-2
/
-WT than
Shp-2+/
-WT chimeric embryos detected at
10.5 d.p.c. might reflect a reduced differentiation capacity
of Shp-2
/
ES cells in culture. We have reported
that Shp-2
/
ES cells had enhanced sensitivity
to the differentiation-inhibitory effect of LIF (25). In
routine ES cell cultures, a higher proportion of totipotent cells was
detected in Shp-2
/
than in WT or
Shp-2+/
ES cell populations (25).

View larger version (66K):
[in this window]
[in a new window]
|
FIG. 1.
Heavily chimeric Shp-2 / -WT
embryos were embryo lethal at midgestation. Pregnant foster females at
10.5 d.p.c. were sacrificed, and embryos were dissected from
maternal tissues and photographed under a dissecting microscope,
followed by genomic DNA extraction and PCR analysis. Chimerism was
determined by PCR detection of the Shp-2 mutant
allele in embryonic cells.
|
|
The contribution of Shp-2
/
cells to various
tissues in chimeric animals was assessed by PCR and Southern blot
analyses that distinguish WT and mutant Shp-2 alleles. Shown in
Fig. 2a are representative results for
PCR analysis of relative contributions of
Shp-2
/
and WT cells to neonatal animals that
survived 2, 5, and 30 days. The life span of chimeras seemed to be
inversely correlated with the contribution of
Shp-2
/
cells. One animal that died 2 days after
birth had a relatively high contribution of
Shp-2
/
cells to many tissues examined,
including brain, heart, kidney, lung, liver, and muscle tissues. The
other two mice, which survived for 5 and 30 days, had increasingly
lower contributions of mutant cells. Shown in Fig. 2b is the result of
Southern blot analysis of various tissues isolated from another
chimeric animal that survived for 5 days. Notably, little or no
contribution of Shp-2
/
cells in these chimeras
was detected in hematopoietic or lymphocytic organs, such as the spleen
and thymus, suggesting a block to blood cell development by the
Shp-2 mutation in vivo.

View larger version (46K):
[in this window]
[in a new window]
|
FIG. 2.
Contribution of Shp-2 / cells to
various tissues in chimeric mice. (a) Three chimeric mice that survived
for 2, 5, and 30 days were dissected. Genomic DNA was extracted from
the eyes, muscle, intestine, thymus, brain, kidney, lung, spleen,
liver, and heart. Shp-2 mutant (mt) and WT (wt) alleles were
detected by PCR with specific pairs of primers (29). The
density of DNA bands reflects the relative contributions of
Shp-2 / ES cells versus those of the parental
embryo. (b) Tissues from a chimeric pup were dissected, and isolated
genomic DNA was subjected to Southern blot analysis with a
[ -32P]dCTP-labelled specific probe (29).
The relative contributions from mutant cells and the parental embryo
were determined by comparing the densities of a 4.2-kb mutant DNA band
and a 3.7-kb WT DNA band.
|
|
Lack of Shp-2
/
progenitor cells in bone
marrow.
As previously reported, we found that the Shp-2
mutation dramatically reduced the development of erythroid and myeloid
progenitors from ES cells in vitro (26). By generating
chimeric animals, we hoped to examine the effect of the Shp-2
mutation on hematopoiesis in vivo by assessing hematopoietic progenitor
cells in the bone marrow and fetal liver. As
Shp-2+/
and Shp-2
/
cells
contain one and two copies of the neomycin resistance gene, respectively, mutant progenitor cells in chimeras were detected by a
combination of G418 selection in CFU assays and PCR analysis of
isolated cell colonies for the Shp-2 mutant allele.
In preliminary experiments, we set up the CFU assay with cells isolated
from Shp-2+/
-WT chimeras by adding different
concentrations of G418 in the culture medium. Colonies resistant to 1 mg of G418/ml were individually picked for PCR analysis, and all clones
were found to be of Shp-2+/
origin (data not
shown). No colonies grew from WT CD1 bone marrow cells under these
selection conditions. In subsequent experiments, CFU assays were set up
in triplicate cultures with or without G418 (1.25 mg/ml) to assess the
relative contribution of Shp-2+/
or
Shp-2
/
ES cells versus that of the WT host
embryo. This method has been successfully used in evaluating the
contribution of SCL/tal-1
/
ES cells to blood cell
lineages in chimeric animals (27).
To examine the effect of the Shp-2 mutation on adult blood cell
development, we isolated bone marrow cells and set up the CFU assay for
BFU-E, CFU-GM, and CFU-GEMM cells. We examined three Shp-2+/
-WT and five
Shp-2
/
-WT adult animals; the results are
shown in Fig. 3. While 7.9 to 79.3% of
the colonies of BFU-E, CFU-GM, and CFU-GEMM cells were derived from
Shp-2+/
ES cells, no contribution of
Shp-2
/
cells to erythroid or myeloid cell
lineages was found. This indicates that Shp-2
/
ES cells failed to contribute to definitive blood cell development even
in a normal bone marrow environment.

View larger version (36K):
[in this window]
[in a new window]
|
FIG. 3.
Detection of hematopoietic progenitors in the bone
marrow of Shp-2 / -WT chimeras. Bone marrow
cells of two femurs from each of five
Shp-2 / -WT and three
Shp-2+/ -WT chimeras were flushed out and
disaggregated into single-cell suspensions. Nucleated cells (5.0 × 104/ml) were seeded into semisolid methylcellulose CFU
assay culture systems with and without G418 at a concentration of 1.25 mg/ml, as described in the text. After 6 to 7 days of incubation,
colonies of BFU-E, CFU-GM, and CFU-GEMM cells grown in cultures without
G418 were scored as total progenitor cells, and colonies grown in
G418-containing medium were enumerated as mutant ES cell-derived
progenitor cells.
|
|
The Shp-2 mutation blocks definitive hematopoiesis in the
fetal liver.
The absence of Shp-2
/
cells
in the bone marrow of chimeras described above could be due to the poor
contribution of Shp-2
/
cells to surviving
chimeras in general (Fig. 2). To further define the effect of the
Shp-2 mutation on blood cell development, we examined
hematopoietic progenitor cells in the livers of chimeric embryos at
14.5 d.p.c. Fetal livers were carefully dissected free of maternal
tissues and other embryonic tissues and disaggregated mechanically into
single-cell suspensions. The cells were plated in a CFU assay
system which contained combinations of hematopoietic growth
factors with or without G418. Other portions of the embryos were used
for DNA extraction and Southern blot analysis. As shown in Fig.
4, of 10 Shp-2
/
-WT chimeric embryos examined, none
had more than 1% contribution from the Shp-2
/
cells to hematopoietic progenitors in the fetal liver, although the
contribution by the mutant ES cells in whole animals was 31 to 63%,
according to the Southern blot analysis (Fig.
5). Meanwhile, the contribution of
Shp-2+/
ES cells to hematopoietic progenitors in
six Shp-2+/
-WT chimeric embryos was from 4.5 to 67.6%, a frequency consistent with the contribution in whole
animals. Therefore, despite the significant contribution of
Shp-2
/
ES cells to many other tissues in
chimeras, Shp-2
/
hematopoietic progenitor cells
in the fetal liver and bone marrow were hardly detectable.

View larger version (47K):
[in this window]
[in a new window]
|
FIG. 4.
Definitive hematopoietic cell development in chimeric
fetal livers. Shp-2 / -WT and
Shp-2+/ -WT chimeric embryos were dissected
at 14.5 d.p.c. Individual fetal livers were isolated in -MEM
plus 15% FCS and disaggregated mechanically into single-cell
suspensions. Nucleated cells (2.5 × 104/ml) were
plated for CFU assays as described in the legend to Fig. 3. After 6 to
7 days of culture, total and ES cell-contributed BFU-E, CFU-GM, and
CFU-GEMM progenitor cells were scored for each fetal liver.
|
|

View larger version (38K):
[in this window]
[in a new window]
|
FIG. 5.
Contribution of Shp-2 / cells in
whole embryos. Chimeric and nonchimeric embryos were dissected at
14.5 d.p.c. and subjected to genomic DNA extraction. Southern blot
analysis was performed for determination of the relative contribution
of Shp-2 / cells versus that of the parental
embryo, as described in the legend to Fig. 2b. Densitometry of the WT
(wt) and mutant (mt) bands showed that the percent contribution from ES
cells for the five chimeras, from left to right, was 31.1, 35.1, 44.8, 63.0, and 41.4.
|
|
Hematopoiesis was deficient in Shp-2
/
yolk
sacs.
In order to determine at which stage hematopoiesis was
blocked by the Shp-2 mutation, embryos were dissected to
examine hematopoiesis in yolk sacs at 8.5 to 9.0 d.p.c. Yolk sacs
were individually dissected and dissociated into single-cell
suspensions for CFU assay. The data shown in Fig.
6 indicates that hematopoietic activity in Shp-2
/
embryos was severely suppressed,
although Shp-2+/
embryos had the WT phenotype. We
had found previously that Shp-2
/
yolk sacs
appeared abnormally thin and wrinkled (29). Thus, Shp-2 plays a critical role in both primitive and definitive
blood cell development and might act at a very early stage of
hematopoietic stem and/or progenitor cell commitment and
differentiation.

View larger version (15K):
[in this window]
[in a new window]
|
FIG. 6.
Defective hematopoiesis in
Shp-2 / yolk sacs. Yolk sacs at 8.5 to 9.0 d.p.c. from Shp-2+/ × Shp-2+/ crosses were carefully dissected free of
maternal tissues under sterile conditions in -MEM plus 15% FCS and
were disaggregated by passing them through a 22-gauge needle. After
being washed once in -MEM, whole yolk sac cells were plated for the
CFU assay. Error bars indicate standard deviations.
|
|
Multiple developmental defects in
Shp-2
/
-WT chimeras.
As revealed by
PCR and Southern blot analyses (Fig. 2), Shp-2
/
cells contributed to many other nonhematopoietic tissues in chimeras, with high levels in muscle and brain tissues. An obvious defect in
terminally developed Shp-2
/
-WT chimeras
was the abnormal formation of the hind limbs, lumbar vertebrae, and rib
patterning (Fig. 7). The development of
hind limbs either stopped with the femur stage or continued to the end
with incomplete digit formation. In total, 78% of
Shp-2
/
-WT chimeras had short hind legs or
abnormal limb features on one or both sides. In many chimeric animals,
the structures of lumbar vertebrae were split, with several
ossification centers and a large cell mass in one vertebral body.
Abnormal patterning of the ribs often resulted in the formation of more
or fewer than the 13 pairs found in WT animals. Two costal cartilages
were combined before the junction of the costal cartilage and the
sternebrae. These results suggest that Shp-2 is involved in
mediating the development of terminal and skeletal structures.

View larger version (69K):
[in this window]
[in a new window]
|
FIG. 7.
Abnormalities of terminal and skeletal structures in
Shp-2 / -WT chimeras. (a) Examples from one
nonchimeric animal and two chimeric animals are shown. Chimeras were
recognized by agouti eye color at birth. The abnormality in hind-leg
development was obvious. (b) Newborn
Shp-2 / -WT chimeric pups and nonchimeric
controls were eviscerated and fixed in 100% ethanol and acetone.
Skeletal specimens were prepared as described in the text. Structural
changes were examined and photographed under a dissecting microscope.
(c) WT animal; (A and D) typical representatives of
Shp-2 / -WT chimeras; (B) WT mouse hind foot
with five fingers and four different abnormal feet from
Shp-2 / -WT chimeric mice.
|
|
Anatomical and histological examinations also revealed developmental
defects in the lung and intestine in chimeras. Consistent with the
breathing difficulties observed in the chimeric neonates, atelectasis
within the lung tissue of many chimeras was detected (Fig.
8a), similar to what is often seen in
immature human babies with respiratory distress syndrome
(20). The alveolar septae were thicker and hypercellular
compared to the thin alveolar epithelium of a normal lung (Fig. 8b). A
severe gastrointestinal problem was also noticed, as many newborn
chimeric mice had feeding problems, with no milk observed in the
stomach upon dissection. The intestines were also distended, with a
very thin muscle layer, and were often dilated with free gas.
Twenty-eight of 42 (66.7%) Shp-2
/
-WT
chimeric mice were found dead at birth or died in a couple of days with
obvious breathing or feeding difficulties. In contrast, none of the
chimeric mice derived from Shp-2+/
or WT ES cells
were found dead or had any developmental defects. Taken together, these
results indicate that Shp-2 is essential for mouse
hematopoiesis and is also involved in mediating development of many
other tissues.

View larger version (149K):
[in this window]
[in a new window]
|
FIG. 8.
Histopathological changes in the lungs of
Shp-2 / -WT chimeric mice. (a) Mutant lung
section, with hypercellular thickened alveolar walls; (b) lung of
normal newborn, with thin alveolar walls and well-developed alveolar
spaces. Magnification, ×100. Hematoxylin and eosin staining was
used.
|
|
 |
DISCUSSION |
In this report, we present evidence that Shp-2 is involved
in mediating the normal development of multiple tissues, with an important role in hematopoiesis. Generation of definitive
hematopoietic progenitor cells from
Shp-2
/
ES cells was blocked in the fetal liver
and bone marrow in chimeric animals. However,
Shp-2+/
cells steadily contributed to both
erythroid and myeloid cell lineages, in a proportion consistent with
their overall contribution in chimeras. This observation, while
confirming our previous result that the Shp-2 mutation blocks
hematopoietic cell differentiation from ES cells in vitro
(26), also indicates that the hematopoietic defect is cell
autonomous.
Although the nature of the requirement for Shp-2 in
hematopoiesis is unclear at this stage, it is very likely that
Shp-2 might act at multiple "checkpoints" of hierarchical
blood cell differentiation during embryogenesis. Shp-2 is
highly expressed in undifferentiated and differentiating ES cells at
various stages as well as in developing mouse embryos (5,
26). Our previous reverse transcriptase PCR analysis detected the
expression of several marker genes for hematopoietic progenitor cells,
such s CD34 and AIC-2B, in Shp-2
/
embryoid bodies, albeit at reduced levels (26). This would suggest that the Shp-2 mutation did not completely
block the commitment of hematopoietic stem and progenitor cells.
However, the Shp-2
/
progenitors, if any,
are apparently defective in their further development into mature blood
cells, as revealed in this study. Presumably, Shp-2 is involved
in cytoplasmic signaling pathways that regulate the proliferation and
differentiation of hematopoietic stem and progenitor cells. Treatment
of ES cells with SCF induced Erk kinase activation, but this induction
was completely blocked in Shp-2
/
ES cells
(26). We have also found that Shp-2 physically
interacts with and gets tyrosine phosphorylated by the c-kit
receptor kinase upon SCF binding in blood cells (35). These
biochemical data strongly support the notion that Shp-2 is a
critical signal transducer downstream of c-kit in mediating
hematopoiesis. Further investigation would involve the physical
enrichment of any Shp-2
/
progenitor cells and
determination of signaling defects that are responsible for the
impaired differentiation capacity. Complementation of
Shp-2
/
ES cells with constitutively active
mutants in the Ras-Erk kinase pathway may also help us to define the
molecular basis for Shp-2 function in cytoplasmic signaling for
hematopoiesis.
Chimeric animal analysis has provided an unprecedented opportunity to
identify the functions of genes involved in the regulation of the
developmental behavior of hematopoietic stem cells. This approach has
yielded fundamental insights into the molecular mechanism of control of
hematopoiesis by several transcription factors, including GATA-2 and
SCL/tal-1 (24, 27, 37). Deletion of the genes blocked
development of all blood cell lineages in chimeric animals, while
no obvious pathological changes were found in other tissues, due to the
specific gene expression pattern. We now demonstrate that this system
can also be of great value in dissecting functions of a widely
expressed gene, such as Shp-2. In this case,
chimeric analysis not only reveals a requirement for an essential gene in the control of hematopoiesis but also uncovers its functional involvement in the differentiation and functions of various tissues, which are otherwise masked by the early embryonic lethality of homozygous mutant animals. Thus, this approach will allow detection of
a biased suppression of different physiological processes by a specific
gene mutation. In this study, we have shown that Shp-2 plays an
indispensable role in hematopoiesis, while its functional involvement
in other systems could be compensated to a certain degree, resulting in
mild-to-severe pathological changes in various organs.
Previous studies have indicated that Shp-2 plays a critical
role during gastrulation in the formation of axial mesodermal (node and notochord) and paraxial mesodermal (somite)
structures (29). Development and posterior elongation of the
notochord from the node is severely impaired, delayed, or incomplete.
In severely affected Shp-2
/
embryos, there is
not even a distinguishable node. The well-developed animals display
varying degrees of posterior truncation and lateral projection of the
notochord. The development of somites is also blocked or severely
reduced. In the present study, we observed a corresponding abnormal
phenotype at later stages of development in
Shp-2
/
-WT chimeric animals. Consistent
with the defects in the notochord in Shp-2
/
embryos, the Shp-2 deficiency caused split lumbar vertebra
structures with abnormal cell accumulation in one vertebral body in
chimeras. In addition, most chimeric mice displayed truncations of
terminal structures, as evidenced by short legs or aberrant digit
formation. These results are consistent with those of a previous study
showing that interference with Shp-2 function by injecting a
catalytically inactive Shp-2 mutant mRNA into
Xenopus embryos caused severe posterior truncations
(34). Limb bud initiation and subsequent patterning in
development is derived from immediate mesoderm (10). In this
process, fibroblast growth factors (FGFs) play a central role and
stimulate the outgrowth of cells located in the limb bud. FGFs are
highly expressed in this area and are closely linked to the
determination of cell fate in limb development. Biochemical evidence
indicates that Shp-2 is a positive signal transducer downstream
of FGF receptors in mediating the activation of Erk kinases (29,
34). A similar defect in axial mesodermal patterning and early
postimplantation development was also observed in FGFR-1 knockout
mice (3, 40). Therefore, defective FGF signaling caused by
the Shp-2 mutation might explain in part the abnormalities in
terminal and skeletal structures in
Shp-2
/
-WT chimeric animals. In addition,
we have observed that Shp-2
/
fibroblasts, like
focal adhesion kinase (FAK)-deficient cells (9), are
impaired in their ability to migrate and spread on fibronectin and
display an increased number of focal adhesion sites (41).
Interestingly, FAK
/
embryos die at midgestation with a
phenotype similar to that of Shp-2 mutant embryos, having
severe defects in mesodermal patterning and posterior truncations
(7, 9). These results suggest that Shp-2 might work
in concert with FAK in mediating the formation of posterior structures
during mouse development.
In summary, we provide genetic evidence that Shp-2, a
widely expressed phosphatase, participates in a variety of
intracellular signaling pathways and functions at different
developmental stages. In hematopoiesis, Shp-2 might be required
in the commitment and differentiation of hematopoietic stem and/or
progenitor cells.
 |
ACKNOWLEDGMENTS |
We thank Andras Nagy, Stuart H. Orkin, Fong-Ying Tsai, Phillippe
Soriano, and Mark Kaplan as well as other members of our laboratory for
helpful discussion and critical reading of the manuscript.
This work was partially supported by grants from the National
Institutes of Health (R29GM53660), the American Heart
Association-Indiana Affiliate Inc., and the Indiana University Cancer
Center to G.-S.F. and by NIH R01 grant HL56416 to H.E.B. G.-S.F.
had a career development award from the American Diabetes Association.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Walther Oncology
Center, Indiana University School of Medicine, 1044 W. Walnut St. Room
302, Indianapolis, IN 46202-5254. Phone: (317) 274-7515. Fax: (317)
274-7592. E-mail: gfeng{at}iupui.edu.
 |
REFERENCES |
| 1.
|
Bash, R. O.,
S. Hall,
C. F. Timmons,
W. M. Crist,
M. Amylon,
R. G. Smith, and R. Baer.
1995.
Does activation of the TAL1 gene occur in a majority of patients with T-cell acute lymphoblastic leukemia? A pediatric oncology group study.
Blood
86:666-676[Abstract/Free Full Text].
|
| 2.
| Cooper, S., and H. E. Broxmeyer. 1996. Measurement of interleukin-3 and other hematopoietic growth factors,
such as GM-CSF, G-CSF, M-CSF, erythropoietin and the other potent
co-stimulating cytokines steel factor and Flt-3 ligand. Curr. Protocols
Immunol. 18(Suppl.):6.4.1-6.4.12.
|
| 3.
|
Deng, C. X.,
A. Wynshaw-Boris,
M. M. Shen,
C. Daugherty,
D. M. Ornitz, and P. Leder.
1994.
Murine FGFR-1 is required for early postimplantation growth and axial organization.
Genes Dev.
8:3045-3057[Abstract/Free Full Text].
|
| 4.
|
de Vries, C.,
J. A. Escobedo,
H. Ueno,
K. Houck,
N. Ferrara, and L. T. Williams.
1992.
The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor.
Science
255:989-991[Abstract/Free Full Text].
|
| 5.
|
Feng, G. S.,
C. C. Hui, and T. Pawson.
1993.
SH2-containing phosphotyrosine phosphatase as a target of protein-tyrosine kinases.
Science
259:1607-1611[Abstract/Free Full Text].
|
| 6.
|
Feng, G. S., and T. Pawson.
1994.
Phosphotyrosine phosphatases with SH2 domains: regulators of signal transduction.
Trends Genet.
10:54-58[Medline].
|
| 7.
|
Furuta, Y.,
D. Ilic,
S. Kanazawa,
N. Takeda,
T. Yamamoto, and S. Aizawa.
1995.
Mesodermal defect in late phase of gastrulation by a targeted mutation of focal adhesion kinase, FAK.
Oncogene
11:1989-1995[Medline].
|
| 8.
|
Georgopoulos, K.,
M. Bigby,
J. H. Wang,
A. Molnar,
P. Wu,
S. Winandy, and A. Sharpe.
1994.
The Ikaros gene is required for the development of all lymphoid lineages.
Cell
79:143-156[Medline].
|
| 9.
|
Ilic, D.,
Y. Furuta,
S. Kanazawa,
N. Takeda,
K. Sobue,
N. Nakatsuji,
S. Nomura,
J. Fujimoto,
M. Okada,
T. Yamamoto, et al.
1995.
Reduced cell motility and enhanced focal adhesion contact formation in cells from FAK-deficient mice.
Nature
377:539-544[Medline].
|
| 10.
|
Johnson, R. L., and C. J. Tabin.
1997.
Molecular models for vertebrate limb development.
Cell
90:979-990[Medline].
|
| 11.
|
Keller, G. M.
1995.
In vitro differentiation of embryonic stem cells.
Curr. Opin. Cell. Biol.
7:862-869[Medline].
|
| 12.
|
Kessel, M., and P. Gruss.
1991.
Homeotic transformations of murine vertebrae and concomitant alteration of Hox codes induced by retinoic acid.
Cell
67:89-104[Medline].
|
| 13.
|
Matthews, W.,
C. T. Jordan,
G. W. Wiegand,
D. Pardoll, and I. R. Lemischka.
1991.
A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations.
Cell
65:1143-1152[Medline].
|
| 14.
|
Milarski, K. L., and A. R. Saltiel.
1994.
Expression of catalytically inactive Syp phosphatase in 3T3 cells blocks stimulation of mitogen-activated protein kinase by insulin.
J. Biol. Chem.
269:21239-21243[Abstract/Free Full Text].
|
| 15.
|
Mortensen, R. M.,
D. A. Conner,
S. Chao,
A. A. T. Geisterfer-Lowrance, and J. G. Seidman.
1992.
Production of homozygous mutant ES cells with a single targeting construct.
Mol. Cell. Biol.
12:2391-2395[Abstract/Free Full Text].
|
| 16.
|
Mucenski, M. L.,
K. McLain,
A. B. Kier,
S. H. Swerdlow,
C. M. Schreiner,
T. A. Miller,
D. W. Pietryga,
W. J. Scott, Jr., and S. S. Potter.
1991.
A functional c-myb gene is required for normal murine fetal hepatic hematopoiesis.
Cell
65:677-689[Medline].
|
| 17.
|
Nagy, A.,
J. Rossant,
R. Nagy,
W. Abramow-Newerly, and J. C. Roder.
1993.
Derivation of completely cell culture-derived mice from early-passage embryonic stem cells.
Proc. Natl. Acad. Sci. USA
90:8424-8428[Abstract/Free Full Text].
|
| 18.
|
Neel, B. G., and N. K. Tonks.
1997.
Protein tyrosine phosphatases in signal transduction.
Curr. Opin. Cell Biol.
9:193-204[Medline].
|
| 19.
|
Noguchi, T.,
T. Matozaki,
K. Horita,
Y. Fujioka, and M. Kasuga.
1994.
Role of SH-PTP2, a protein-tyrosine phosphatase with Src homology 2 domains, in insulin-stimulated Ras activation.
Mol. Cell. Biol.
14:6674-6682[Abstract/Free Full Text].
|
| 20.
|
Oh, W., and L. Stern.
1987.
Respiratory diseases of the newborn, p. 395.
In
L. Stern, and P. Vert (ed.), Neonatal medicine. Masson Publishing USA, Inc., New York, N.Y.
|
| 21.
|
Okuda, T.,
J. van Deursen,
S. W. Hiebert,
G. Grosveld, and J. R. Downing.
1996.
AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis.
Cell
84:321-330[Medline].
|
| 22.
|
Orkin, S. H.
1995.
Hematopoiesis: how does it happen?
Curr. Opin. Cell Biol.
7:870-877[Medline].
|
| 23.
|
Pevny, L.,
M. C. Simon,
E. Robertson,
W. H. Klein,
S. F. Tsai,
V. D'Agati,
S. H. Orkin, and F. Costantini.
1991.
Erythroid differentiation in chimaeric mice blocked by a targeted mutation in the gene for transcription factor GATA-1.
Nature
349:257-260[Medline].
|
| 24.
|
Porcher, C.,
W. Swat,
K. Rockwell,
Y. Fujiwara,
F. W. Alt, and S. H. Orkin.
1996.
The T cell leukemia oncoprotein SCL/tal-1 is essential for development of all hematopoietic lineages.
Cell
86:47-57[Medline].
|
| 25.
|
Qu, C. K., and G. S. Feng.
1998.
Shp-2 has a positive regulatory role in ES cell differentiation and proliferation.
Oncogene
17:433-440[Medline].
|
| 26.
|
Qu, C.-K.,
Z.-Q. Shi,
R. Shen,
F.-Y. Tsai,
S. H. Orkin, and G.-S. Feng.
1997.
A deletion mutation in the SH2-N domain of Shp-2 severely suppresses hematopoietic cell development.
Mol. Cell. Biol.
17:5499-5507[Abstract].
|
| 27.
|
Robb, L.,
N. J. Elwood,
A. G. Elefanty,
F. Kontgen,
R. Li,
L. D. Barnett, and C. G. Begley.
1996.
The scl gene product is required for the generation of all hematopoietic lineages in the adult mouse.
EMBO J.
15:4123-4129[Medline].
|
| 28.
|
Roche, S.,
J. McGlade,
M. Jones,
G. D. Gish,
T. Pawson, and S. A. Courtneidge.
1996.
Requirement of phospholipase C gamma, the tyrosine phosphatase Syp and the adaptor proteins Shc and Nck for PDGF-induced DNA synthesis: evidence for the existence of Ras-dependent and Ras-independent pathways.
EMBO J.
15:4940-4948[Medline].
|
| 29.
|
Saxton, T. M.,
M. Henkemeyer,
S. Gasca,
R. Shen,
F. Shalaby,
G. S. Feng, and T. Pawson.
1997.
Abnormal mesoderm patterning in mouse embryos mutant for the SH2 tyrosine phosphatase Shp-2.
EMBO J.
16:2352-2364[Medline].
|
| 30.
|
Scott, E. W.,
M. C. Simon,
J. Anastasi, and H. Singh.
1994.
Requirement of transcription factor PU.1 in the development of multiple hematopoietic lineages.
Science
265:1573-1577[Abstract/Free Full Text].
|
| 31.
|
Shalaby, F.,
J. Ho,
W. L. Stanford,
K. D. Fischer,
A. C. Schuh,
L. Schwartz,
A. Bernstein, and J. Rossant.
1997.
A requirement for Flk1 in primitive and definitive hematopoiesis and vasculogenesis.
Cell
89:981-990[Medline].
|
| 32.
|
Shalaby, F.,
J. Rossant,
T. P. Yamaguchi,
M. Gertsenstein,
X. F. Wu,
M. L. Breitman, and A. C. Schuh.
1995.
Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice.
Nature
376:62-66[Medline].
|
| 33.
|
Shi, Z. Q.,
W. Lu, and G. S. Feng.
1998.
The Shp-2 tyrosine phosphatase has opposite effects in mediating the activation of extracellular signal-regulated and c-Jun NH2-terminal mitogen-activated protein kinases.
J. Biol. Chem.
273:4892-4896[Abstract/Free Full Text].
|
| 34.
|
Tang, T. L.,
R. Freeman, Jr.,
A. M. O'Reilly,
B. G. Neel, and S. Y. Sokol.
1995.
The SH2-containing protein-tyrosine phosphatase SH-PTP2 is required upstream of MAP kinase for early Xenopus development.
Cell
80:473-483[Medline].
|
| 35.
|
Tauchi, T.,
G. S. Feng,
M. S. Marshall,
R. Shen,
C. Mantel,
T. Pawson, and H. E. Broxmeyer.
1994.
The ubiquitously expressed Syp phosphatase interacts with c-kit and Grb2 in hematopoietic cells.
J. Biol. Chem.
269:25206-25211[Abstract/Free Full Text].
|
| 36.
|
Tauchi, T.,
G. S. Feng,
R. Shen,
M. Hoatlin,
G. Bagby, Jr.,
D. Kabat,
L. Lu, and H. E. Broxmeyer.
1995.
Involvement of SH2-containing phosphotyrosine phosphatase Syp in erythropoietin receptor signal transduction pathways.
J. Biol. Chem.
270:5631-5635[Abstract/Free Full Text].
|
| 37.
|
Tsai, F. Y.,
G. Keller,
F. C. Kuo,
M. Weiss,
J. Chen,
M. Rosenblatt,
F. W. Alt, and S. H. Orkin.
1994.
An early haematopoietic defect in mice lacking the transcription factor GATA-2.
Nature
371:221-226[Medline].
|
| 38.
|
Weiss, M. J.,
G. Keller, and S. H. Orkin.
1994.
Novel insights into erythroid development revealed through in vitro differentiation of GATA-1 embryonic stem cells.
Genes Dev.
8:1184-1197[Abstract/Free Full Text].
|
| 39.
|
Weiss, M. J., and S. H. Orkin.
1995.
Transcription factor GATA-1 permits survival and maturation of erythroid precursors by preventing apoptosis.
Proc. Natl. Acad. Sci. USA
92:9623-9627[Abstract/Free Full Text].
|
| 40.
|
Yamaguchi, T. P.,
K. Harpal,
M. Henkemeyer, and J. Rossant.
1994.
FGFR-1 is required for embryonic growth and mesodermal patterning during mouse gastrulation.
Genes Dev.
8:3032-3044[Abstract/Free Full Text].
|
| 41.
|
Yu, D. H.,
C. K. Qu,
O. Henegariu,
X. Lu, and G. S. Feng.
1998.
Protein tyrosine phosphatase Shp-2 regulates cell spreading, migration and focal adhesion.
J. Biol. Chem.
273:21125-21131[Abstract/Free Full Text].
|
Molecular and Cellular Biology, October 1998, p. 6075-6082, Vol. 18, No. 10
0270-7306/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Krajewska, M., Banares, S., Zhang, E. E., Huang, X., Scadeng, M., Jhala, U. S., Feng, G.-S., Krajewski, S.
(2008). Development of Diabesity in Mice with Neuronal Deletion of Shp2 Tyrosine Phosphatase. Am. J. Pathol.
172: 1312-1324
[Abstract]
[Full Text]
-
Ke, Y., Zhang, E. E., Hagihara, K., Wu, D., Pang, Y., Klein, R., Curran, T., Ranscht, B., Feng, G.-S.
(2007). Deletion of Shp2 in the Brain Leads to Defective Proliferation and Differentiation in Neural Stem Cells and Early Postnatal Lethality. Mol. Cell. Biol.
27: 6706-6717
[Abstract]
[Full Text]
-
Broxmeyer, H. E., Sehra, S., Cooper, S., Toney, L. M., Kusam, S., Aloor, J. J., Marchal, C. C., Dinauer, M. C., Dent, A. L.
(2007). Aberrant Regulation of Hematopoiesis by T Cells in BAZF-Deficient Mice. Mol. Cell. Biol.
27: 5275-5285
[Abstract]
[Full Text]
-
Chan, R. J., Feng, G.-S.
(2007). PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase. Blood
109: 862-867
[Abstract]
[Full Text]
-
Chen, J., Yu, W.-M., Daino, H., Broxmeyer, H. E., Druker, B. J., Qu, C.-K.
(2007). SHP-2 phosphatase is required for hematopoietic cell transformation by Bcr-Abl. Blood
109: 778-785
[Abstract]
[Full Text]
-
Wilson, M. D., Cheung, J., Martindale, D. W., Scherer, S. W., Koop, B. F.
(2006). Comparative analysis of the paired immunoglobulin-like receptor (PILR) locus in six mammalian genomes: duplication, conversion, and the birth of new genes. Physiol. Genomics
27: 201-218
[Abstract]
[Full Text]
-
Bard-Chapeau, E. A., Yuan, J., Droin, N., Long, S., Zhang, E. E., Nguyen, T. V., Feng, G.-S.
(2006). Concerted Functions of Gab1 and Shp2 in Liver Regeneration and Hepatoprotection. Mol. Cell. Biol.
26: 4664-4674
[Abstract]
[Full Text]
-
Verbrugge, A., de Ruiter, T., Geest, C., Coffer, P. J., Meyaard, L.
(2006). Differential expression of leukocyte-associated Ig-like receptor-1 during neutrophil differentiation and activation. J. Leukoc. Biol.
79: 828-836
[Abstract]
[Full Text]
-
Yu, W.-M., Daino, H., Chen, J., Bunting, K. D., Qu, C.-K.
(2006). Effects of a Leukemia-associated Gain-of-Function Mutation of SHP-2 Phosphatase on Interleukin-3 Signaling. J. Biol. Chem.
281: 5426-5434
[Abstract]
[Full Text]
-
Zou, G.-M., Chan, R. J., Shelley, W. C., Yoder, M. C.
(2006). Reduction of Shp-2 Expression by Small Interfering RNA Reduces Murine Embryonic Stem Cell-Derived In Vitro Hematopoietic Differentiation. Stem Cells
24: 587-594
[Abstract]
[Full Text]
-
Yuan, L., Yu, W.-M., Xu, M., Qu, C.-K.
(2005). SHP-2 Phosphatase Regulates DNA Damage-induced Apoptosis and G2/M Arrest in Catalytically Dependent and Independent Manners, Respectively. J. Biol. Chem.
280: 42701-42706
[Abstract]
[Full Text]
-
Sithanandam, G., Smith, G. T., Fields, J. R., Fornwald, L. W., Anderson, L. M.
(2005). Alternate Paths from Epidermal Growth Factor Receptor to Akt in Malignant Versus Nontransformed Lung Epithelial Cells: ErbB3 Versus Gab1. Am. J. Respir. Cell Mol. Bio.
33: 490-499
[Abstract]
[Full Text]
-
Xu, R., Yu, Y., Zheng, S., Zhao, X., Dong, Q., He, Z., Liang, Y., Lu, Q., Fang, Y., Gan, X., Xu, X., Zhang, S., Dong, Q., Zhang, X., Feng, G.-S.
(2005). Overexpression of Shp2 tyrosine phosphatase is implicated in leukemogenesis in adult human leukemia. Blood
106: 3142-3149
[Abstract]
[Full Text]
-
Bunting, K. D., Yu, W.-M., Bradley, H. L., Haviernikova, E., Kelly-Welch, A. E., Keegan, A. D., Qu, C.-K.
(2004). Increased numbers of committed myeloid progenitors but not primitive hematopoietic stem/progenitors in mice lacking STAT6 expression. J. Leukoc. Biol.
76: 484-490
[Abstract]
[Full Text]
-
Tartaglia, M., Martinelli, S., Cazzaniga, G., Cordeddu, V., Iavarone, I., Spinelli, M., Palmi, C., Carta, C., Pession, A., Arico, M., Masera, G., Basso, G., Sorcini, M., Gelb, B. D., Biondi, A.
(2004). Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia. Blood
104: 307-313
[Abstract]
[Full Text]
-
Loh, M. L., Vattikuti, S., Schubbert, S., Reynolds, M. G., Carlson, E., Lieuw, K. H., Cheng, J. W., Lee, C. M., Stokoe, D., Bonifas, J. M., Curtiss, N. P., Gotlib, J., Meshinchi, S., Le Beau, M. M., Emanuel, P. D., Shannon, K. M.
(2004). Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis. Blood
103: 2325-2331
[Abstract]
[Full Text]
-
Yuan, L., Yu, W.-M., Qu, C.-K.
(2003). DNA Damage-induced G2/M Checkpoint in SV40 Large T Antigen-immortalized Embryonic Fibroblast Cells Requires SHP-2 Tyrosine Phosphatase. J. Biol. Chem.
278: 42812-42820
[Abstract]
[Full Text]
-
Araki, T., Nawa, H., Neel, B. G.
(2003). Tyrosyl Phosphorylation of Shp2 Is Required for Normal ERK Activation in Response to Some, but Not All, Growth Factors. J. Biol. Chem.
278: 41677-41684
[Abstract]
[Full Text]
-
Chan, R. J., Johnson, S. A., Li, Y., Yoder, M. C., Feng, G.-S.
(2003). A definitive role of Shp-2 tyrosine phosphatase in mediating embryonic stem cell differentiation and hematopoiesis. Blood
102: 2074-2080
[Abstract]
[Full Text]
-
Yuan, L., Yu, W.-M., Yuan, Z., Haudenschild, C. C., Qu, C.-K.
(2003). Role of SHP-2 Tyrosine Phosphatase in the DNA Damage-induced Cell Death Response. J. Biol. Chem.
278: 15208-15216
[Abstract]
[Full Text]
-
Yu, W.-M., Hawley, T. S., Hawley, R. G., Qu, C.-K.
(2002). Immortalization of yolk sac-derived precursor cells. Blood
100: 3828-3831
[Abstract]
[Full Text]
-
Yu, W.-M., Hawley, T. S., Hawley, R. G., Qu, C.-K.
(2002). Role of the docking protein Gab2 in beta 1-integrin signaling pathway-mediated hematopoietic cell adhesion and migration. Blood
99: 2351-2359
[Abstract]
[Full Text]
-
Qu, C.-K., Nguyen, S., Chen, J., Feng, G.-S.
(2001). Requirement of Shp-2 tyrosine phosphatase in lymphoid and hematopoietic cell development. Blood
97: 911-914
[Abstract]
[Full Text]
-
Chernock, R. D., Cherla, R. P., Ganju, R. K.
(2001). SHP2 and cbl participate in {alpha}-chemokine receptor CXCR4-mediated signaling pathways. Blood
97: 608-615
[Abstract]
[Full Text]
-
Car, B. D., Eng, V. M.
(2001). Special Considerations in the Evaluation of the Hematology and Hemostasis of Mutant Mice. Vet Pathol
38: 20-30
[Abstract]
[Full Text]
-
Sachs, M., Brohmann, H., Zechner, D., Muller, T., Hulsken, J., Walther, I., Schaeper, U., Birchmeier, C., Birchmeier, W.
(2000). Essential Role of Gab1 for Signaling by the c-Met Receptor In Vivo. J. Cell Biol.
150: 1375-1384
[Abstract]
[Full Text]
-
Qu, C.-K., Yu, W.-M., Azzarelli, B., Feng, G.-S.
(1999). Genetic evidence that Shp-2 tyrosine phosphatase is a signal enhancer of the epidermal growth factor receptor in mammals. Proc. Natl. Acad. Sci. USA
96: 8528-8533
[Abstract]
[Full Text]
-
You, M., Yu, D.-H., Feng, G.-S.
(1999). Shp-2 Tyrosine Phosphatase Functions as a Negative Regulator of the Interferon-Stimulated Jak/STAT Pathway. Mol. Cell. Biol.
19: 2416-2424
[Abstract]
[Full Text]
-
Ganju, R. K., Brubaker, S. A., Chernock, R. D., Avraham, S., Groopman, J. E.
(2000). beta -Chemokine Receptor CCR5 Signals through SHP1, SHP2, and Syk. J. Biol. Chem.
275: 17263-17268
[Abstract]
[Full Text]